Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus

Nayeon Kim, Joon Hee Kang, Won Kyu Lee, Seul Gi Kim, Jae Seon Lee, Seon Hyeong Lee, Jong Bae Park, Kyung Hee Kim, Young Dae Gong, Kwang Yeon Hwang, Soo Youl Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Previously we have demonstrated transglutaminase 2 (TGase 2) inhibition abrogated renal cell carcinoma (RCC) using GK921 (3-(phenylethynyl)-2-(2-(pyridin-2-yl)ethoxy)pyrido[3,2-b]pyrazine), although the mechanism of TGase 2 inhibition remains unsolved. Recently, we found that the increase of TGase 2 expression is required for p53 depletion in RCC by transporting the TGase 2 (1–139 a.a)–p53 complex to the autophagosome, through TGase 2 (472–687 a.a) binding p62. In this study, mass analysis revealed that GK921 bound to the N terminus of TGase 2 (81–116 a.a), which stabilized p53 by blocking TGase 2 binding. This suggests that RCC survival can be stopped by p53-induced cell death through blocking the p53–TGase 2 complex formation using GK921. Although GK921 does not bind to the active site of TGase 2, GK921 binding to the N terminus of TGase 2 also inactivated TGase 2 activity through acceleration of non-covalent self-polymerization of TGase 2 via conformational change. This suggests that TGase 2 has an allosteric binding site (81–116 a.a) which changes the conformation of TGase 2 enough to accelerate inactivation through self-polymer formation.

Original languageEnglish
Pages (from-to)1583-1594
Number of pages12
JournalAmino Acids
Volume50
Issue number11
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Allosteric Site
Renal Cell Carcinoma
transglutaminase 2
Cells
Cell death
Polymerization

Keywords

  • Allosteric binding site
  • GK921
  • p53
  • Transglutaminase 2

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Kim, N., Kang, J. H., Lee, W. K., Kim, S. G., Lee, J. S., Lee, S. H., ... Kim, S. Y. (2018). Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus. Amino Acids, 50(11), 1583-1594. https://doi.org/10.1007/s00726-018-2635-2

Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus. / Kim, Nayeon; Kang, Joon Hee; Lee, Won Kyu; Kim, Seul Gi; Lee, Jae Seon; Lee, Seon Hyeong; Park, Jong Bae; Kim, Kyung Hee; Gong, Young Dae; Hwang, Kwang Yeon; Kim, Soo Youl.

In: Amino Acids, Vol. 50, No. 11, 01.11.2018, p. 1583-1594.

Research output: Contribution to journalArticle

Kim, N, Kang, JH, Lee, WK, Kim, SG, Lee, JS, Lee, SH, Park, JB, Kim, KH, Gong, YD, Hwang, KY & Kim, SY 2018, 'Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus', Amino Acids, vol. 50, no. 11, pp. 1583-1594. https://doi.org/10.1007/s00726-018-2635-2
Kim N, Kang JH, Lee WK, Kim SG, Lee JS, Lee SH et al. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus. Amino Acids. 2018 Nov 1;50(11):1583-1594. https://doi.org/10.1007/s00726-018-2635-2
Kim, Nayeon ; Kang, Joon Hee ; Lee, Won Kyu ; Kim, Seul Gi ; Lee, Jae Seon ; Lee, Seon Hyeong ; Park, Jong Bae ; Kim, Kyung Hee ; Gong, Young Dae ; Hwang, Kwang Yeon ; Kim, Soo Youl. / Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus. In: Amino Acids. 2018 ; Vol. 50, No. 11. pp. 1583-1594.
@article{a69125762bbc45f1a9c8397fda67fa38,
title = "Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus",
abstract = "Previously we have demonstrated transglutaminase 2 (TGase 2) inhibition abrogated renal cell carcinoma (RCC) using GK921 (3-(phenylethynyl)-2-(2-(pyridin-2-yl)ethoxy)pyrido[3,2-b]pyrazine), although the mechanism of TGase 2 inhibition remains unsolved. Recently, we found that the increase of TGase 2 expression is required for p53 depletion in RCC by transporting the TGase 2 (1–139 a.a)–p53 complex to the autophagosome, through TGase 2 (472–687 a.a) binding p62. In this study, mass analysis revealed that GK921 bound to the N terminus of TGase 2 (81–116 a.a), which stabilized p53 by blocking TGase 2 binding. This suggests that RCC survival can be stopped by p53-induced cell death through blocking the p53–TGase 2 complex formation using GK921. Although GK921 does not bind to the active site of TGase 2, GK921 binding to the N terminus of TGase 2 also inactivated TGase 2 activity through acceleration of non-covalent self-polymerization of TGase 2 via conformational change. This suggests that TGase 2 has an allosteric binding site (81–116 a.a) which changes the conformation of TGase 2 enough to accelerate inactivation through self-polymer formation.",
keywords = "Allosteric binding site, GK921, p53, Transglutaminase 2",
author = "Nayeon Kim and Kang, {Joon Hee} and Lee, {Won Kyu} and Kim, {Seul Gi} and Lee, {Jae Seon} and Lee, {Seon Hyeong} and Park, {Jong Bae} and Kim, {Kyung Hee} and Gong, {Young Dae} and Hwang, {Kwang Yeon} and Kim, {Soo Youl}",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s00726-018-2635-2",
language = "English",
volume = "50",
pages = "1583--1594",
journal = "Amino Acids",
issn = "0939-4451",
publisher = "Springer Wien",
number = "11",

}

TY - JOUR

T1 - Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus

AU - Kim, Nayeon

AU - Kang, Joon Hee

AU - Lee, Won Kyu

AU - Kim, Seul Gi

AU - Lee, Jae Seon

AU - Lee, Seon Hyeong

AU - Park, Jong Bae

AU - Kim, Kyung Hee

AU - Gong, Young Dae

AU - Hwang, Kwang Yeon

AU - Kim, Soo Youl

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Previously we have demonstrated transglutaminase 2 (TGase 2) inhibition abrogated renal cell carcinoma (RCC) using GK921 (3-(phenylethynyl)-2-(2-(pyridin-2-yl)ethoxy)pyrido[3,2-b]pyrazine), although the mechanism of TGase 2 inhibition remains unsolved. Recently, we found that the increase of TGase 2 expression is required for p53 depletion in RCC by transporting the TGase 2 (1–139 a.a)–p53 complex to the autophagosome, through TGase 2 (472–687 a.a) binding p62. In this study, mass analysis revealed that GK921 bound to the N terminus of TGase 2 (81–116 a.a), which stabilized p53 by blocking TGase 2 binding. This suggests that RCC survival can be stopped by p53-induced cell death through blocking the p53–TGase 2 complex formation using GK921. Although GK921 does not bind to the active site of TGase 2, GK921 binding to the N terminus of TGase 2 also inactivated TGase 2 activity through acceleration of non-covalent self-polymerization of TGase 2 via conformational change. This suggests that TGase 2 has an allosteric binding site (81–116 a.a) which changes the conformation of TGase 2 enough to accelerate inactivation through self-polymer formation.

AB - Previously we have demonstrated transglutaminase 2 (TGase 2) inhibition abrogated renal cell carcinoma (RCC) using GK921 (3-(phenylethynyl)-2-(2-(pyridin-2-yl)ethoxy)pyrido[3,2-b]pyrazine), although the mechanism of TGase 2 inhibition remains unsolved. Recently, we found that the increase of TGase 2 expression is required for p53 depletion in RCC by transporting the TGase 2 (1–139 a.a)–p53 complex to the autophagosome, through TGase 2 (472–687 a.a) binding p62. In this study, mass analysis revealed that GK921 bound to the N terminus of TGase 2 (81–116 a.a), which stabilized p53 by blocking TGase 2 binding. This suggests that RCC survival can be stopped by p53-induced cell death through blocking the p53–TGase 2 complex formation using GK921. Although GK921 does not bind to the active site of TGase 2, GK921 binding to the N terminus of TGase 2 also inactivated TGase 2 activity through acceleration of non-covalent self-polymerization of TGase 2 via conformational change. This suggests that TGase 2 has an allosteric binding site (81–116 a.a) which changes the conformation of TGase 2 enough to accelerate inactivation through self-polymer formation.

KW - Allosteric binding site

KW - GK921

KW - p53

KW - Transglutaminase 2

UR - http://www.scopus.com/inward/record.url?scp=85051418193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051418193&partnerID=8YFLogxK

U2 - 10.1007/s00726-018-2635-2

DO - 10.1007/s00726-018-2635-2

M3 - Article

C2 - 30105541

AN - SCOPUS:85051418193

VL - 50

SP - 1583

EP - 1594

JO - Amino Acids

JF - Amino Acids

SN - 0939-4451

IS - 11

ER -